Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Blinatumomab consolidation therapy for DLBCL

John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, outlines the results of a pilot study (NCT03072771) which tested blinatumomab as a consolidation therapy post-autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL). The study showed that blinatumomab consolidation was safe and well tolerated, and 100 days post auto-HSCT (one month post blinatumomab consolidation) 10/10 patients were in complete remission. After a median of 14.5 months of follow-up, 6 patients remained in remission. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.